Pharmacodynamic behavior of liposomal antisense oligonucleotides targeting Her-2/ neu and vascular endothelial growth factor in an ascitic MDA435/ LCC6 human breast cancer model

Cancer Biology and Therapy

Volumn 3, Issue 2, 2004, Pages 197-204

  Waterhouse, Dawn N ^a   Dragowska, Wieslawa H ^a   Gelmon, Karen A ^a   Mayer, Lawrence D ^a,b   Bally, Marcel B ^a,b  

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Antisense oligonucleotide; Liposome; Pharmacodynamic; Pharmacokinetic; Xenograft tumor

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BUFFER; DRUG CARRIER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LIPOSOME; VASCULOTROPIN; DNA BINDING PROTEIN; NUCLEAR PROTEIN; RAG2 PROTEIN, HUMAN; RAG2 PROTEIN, MOUSE; V(D)J RECOMBINATION ACTIVATING PROTEIN 2; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; ASCITES TUMOR; BREAST CANCER; CANCER MODEL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG TARGETING; ENCAPSULATION; FEMALE; HUMAN; HUMAN CELL; INJECTION; MOUSE; NONHUMAN; ONCOGENE NEU; PERITONEUM; PERITONEUM CELL; PLASMA CELL; PROTEIN TARGETING; TISSUE DISTRIBUTION; TUMOR XENOGRAFT; XERORADIOGRAPHY; ANIMAL; ASCITES; CELL CULTURE; DISEASE MODEL; DRUG ANTAGONISM; EXPERIMENTAL NEOPLASM; GENE TARGETING; GENETICS; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE; XENOGRAFT;

ANIMALS; ASCITES; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; FEMALE; GENE TARGETING; HUMANS; LIPOSOMES; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, SCID; MICE, TRANSGENIC; NUCLEAR PROTEINS; OLIGONUCLEOTIDES, ANTISENSE; RECEPTOR, ERBB-2; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 9244233163     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.3.2.622     Document Type: Article

References (46)

1. Gasparini G, Toi M, Gion M, Verderio P, Dittadi R, Hanatani M, et al. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 1997; 89:139-47.
2. Anan K, Morisaki T, Katano M, Ikubo A, Tsukahara Y, Kojima M, et al. Assessment of c-erbB2 and vascular endothelial growth factor mRNA expression in fine-needle aspirates from early breast carcinomas: Preoperative determination of malignant potential. Eur J Surg Oncol 1998; 24:28-33.
3. Senger DR, Van de Water L, Brown LF, Nagy JA, Yeo KT, Yeo TK, et al. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 1993; 12:303-24.
4. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, et al. Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992; 84:1875-87.
5. Axelsson K, Ljung BM, Moore DH 2nd, Thor AD, Chew KL, Edgerton SM, et al. Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. J Natl Cancer Inst 1995; 87:997-1008.
6. Heimann R, Ferguson D, Powers C, Recant WM, Weichselbaum RR, Hellman S. Angiogenesis as a predictor of long-term survival for patients with node-negative breast cancer. J Natl Cancer Inst 1996; 88:1764-9.
7. Araya M, Terashima M, Takagane A, Abe K, Nishizuka S, Yonezawa H, et al. Microvessel count predicts metastasis and prognosis in patients with gastric cancer. J Surg Oncol 1997; 65:232-6.
8. Fox SB Tumour angiogenesis and prognosis. Histopathology 1997; 30:294-301.
9. Petit AM, Rak J, Hung MC, Rockwell P, Goldstein N, Fendly B, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997; 151:1523-30.
10. Kerbel RS, Viloria-Petit A, Klement G, Rak J. 'Accidental' anti-angiogenie drugs, anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. Eur J Cancer 2000; 36:1248-57.
11. Yen L, You XL, Al Moustafa AE, Batist G, Hynes NE, Mader S, et al. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis. Oncogene 2000; 19:3460-9.
12. Pegram MD, Reese DM. Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor. Semin Oncol 2002; 29(3 Suppl 11):29-37.
13. Yang W, Klos K, Yang Y, Smith TL, Shi D, Yu D. ErbB2 overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human breast carcinoma. Cancer 2002; 94:2855-61.
14. Kumar R, Yarmand-Bagheri R. The role of HER2 in angiogenesis. Semin Oncol 2001; 28(5 Suppl 16):27-32.
15. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al.Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 12:707-12.
16. Borg A, Tandon AK, Sigurdsson H, Clark GM, Ferno M, Fuqua SA, et al. HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 1990; 50:4332-7.
17. Allred DC, Clark GM, Tandon AK, Molina R, Tormey DC, Osborne CK, et al. HER-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 1992; 10:599-605
18. Sjogren S, Inganas M, Lindgren A, Holmberg L, Bergh J. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 1998; 16:462-9.
19. Pegram MD, Reese DM. Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor. Semin Oncol. 2002; 29:29-37.
20. Leonessa F, Green D, Licht T, Wright A, Wingate-Legette K, Lippman J, et al. MDA435/LCC6 and MDA435/LCC6MDR1: Ascites models of human breast cancer. Br J Cancer 1996; 73:154-61.
21. Levin AA. A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim Biophys Acta 1999; 1489:69-84
22. Shi W and Siemann DW. Inhibition of renal cell carcinoma angiogenesis and growth by antisense oligonucleotides targeting vascular endothelial growth factor. Br J Cancer 2002; 87:119-26.
23. Klasa RJ, Gillum AM, Klem RE, Frankel SR. Oblimersen Bcl-2 antisense: Facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev 2002; 12:193-213.
24. Akhtar S, Agrawal S. In vivo studies with antisense oligonucleotides. Trends Pharmacol Sci 1997; 18:12-8.
25. Masood R, Cai J, Zheng T, Smith DL, Naidu Y, Gill PS. Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma. Proc Natl Acad Sci USA 1997; 94:979-84.
26. Vaughn JP, Stekler J, Demirdji S, Mills JK, Caruthers MH, Iglehart JD, et al. Inhibition of the erbB-2 tyrosine kinase receptor in breast cancer cells by phosphoromonothioate and phosphorodithioate antisense oligonucleotides. Nucl Acids Res 1996; 24:4558-4564.
27. Saxon D, Chia SK, Bally MB. Drug Combinations for Therapy of Aggressive Breast Cancer: Antisense Oligonucleotides Against HER-2/neu. HER2 in Oncology 2000; 1:7-11.
28. Semple SC, Klimuk SK, Harasym TO, Dos Santos N, Ansell SM, Wong KF, et al. Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: Formation of novel small multilamellar vesicle structures. Biochim Biophys Acta 2001; 1510:152-66.
29. Pool GL, French ME, Edwards RA, Huang L, Lumb RH. Use of radiolabeled hexadecyl cholesteryl ether as a liposome marker. Lipids 1982; 17:448-52.
30. Paik S, King CR, Simpson S, Lippman ME. Quantification of erbB-2/neu levels in tissue. Methods Enzymol 1991; 198:290-300.
31. Feng D, Nagy JA, Pyne K, Hammel I, Dvorak HF, Dvorak AM. Pathways of macromolecular extravasation across microvascular endothelium in response to VPF/VEGF and other vasoactive mediators. Microcirculation 1999; 6:23-44.
32. Feng D, Nagy JA, Dvorak AM, Dvorak HF. Different pathways of macromolecule extravasation from hyperpermeable tumor vessels. Microvasc Res 2000; 59:24-37.
33. Bally MB, Masin D, Nayar R, Cullis PR, Mayer LD. Transfer of liposomal drug carriers from the blood to the peritoneal cavity of normal and ascitic tumor-bearing mice. Cancer Chemother Pharmacol 1994; 34:137-46.
34. Cailleau R, Young R, Olive M, Reeves Jr WJ. Breast tumor cell lines from pleural effusions. J Natl Cancer Inst 1974; 53:661-74.
35. Price JE, Zhang RD. Studies of human breast cancer metastasis using nude mice. Cancer Metastasis Rev 1990; 8:285-97.
36. Han S, Yun IJ, Noh DY, Choe KJ, Song SY, Chi JG. Abnormal expression of four novel molecular markers represents a highly aggressive phenotype in breast cancer. Immunohistochemical assay of p53, nm23, erbB-2, and cathepsin D protein. J Surg Oncol 1997; 65:22-7.
37. Ahmad I, Perkins WR, Lupan DM, Selsted ME, Janoff AS. Liposomal entrapment of the neutrophil-derived peptide indolicidin endows it with in vivo antifungal activity. Biochim Biophys Acta 1995; 1237:109-14.
38. Webb MS, Boman NL, Wiseman DJ, Saxon D, Sutton K, Wong KF, et al. Antibacterial efficacy against an in vivo Salmonella typhimurium infection model and pharmacokinetics of a liposomal ciprofloxacin formulation. Antimicrob Agents Chemother 1998; 42:45-52.
39. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994; 54:987-92.
40. Genne P, Olsson NO, Gutierrez G, Duchamp O, Chauffert B. Liposomal mitoxantrone for the local treatment of peritoneal carcinomatosis induced by colon cancer cells in mice. Anticancer Drug Des 1994; 9:73-84.
41. Webb MS, Logan P, Kanter PM, St.-Onge G, Gelmon K, Harasym T, et al. Preclinical pharmacology, toxicology and efficacy of sphingomyelin/cholesterol liposomal vincristine for therapeutic treatment of cancer. Cancer Chemother Pharmacol 1998; 42:461-70.
42. Shapiro CL, Ervin T, Welles L, Azarnia N, Keating J, Hayes DF. Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. TLC D-99 Study Group J Clin Oncol 1999; 17:1435-41.
43. Rait AS, Pirollo KF, Xiang L, Ulick D, Chang EH. Tumor-targeting, systemically delivered antisense HER-2 chemosensitizes human breast cancer xenografts irrespective of HER-2 levels. Mol Med 2002; 8:475-80.
44. Hu Q, Bally MB, Madden TD. Subcellular trafficking of antisense oligonucleotides and down-regulation of bcl-2 gene expression in human melanoma cells using a fusogenic liposome delivery system. Nucleic Acids Res 2002; 30:3632-41.
45. Ma Z, Zhang J, Alber S, Dileo J, Negishi Y, Stolz D, et al. Lipid-mediated delivery of oligonucleotide to pulmonary endothelium. Am J Respir Cell Mol Biol 2002; 27:151-9.
46. Semple SC, Klimuk SK, Harasym TO, Hope MJ. Lipid-based formulations of antisense oligonucleotides for systemic delivery applications. Methods Enzymol 2000; 313:322-41.